Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ahrensburg – page 86

1 437 clinical trials in Ahrensburg, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ahrensburg at a glance
1 437
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 437 trials in Ahrensburg

Open in trial search

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:CLS12311
  • Sponsor:Cellerys AG

Comparison of Post-Transplant Cyclophosphamide versus Anti-T Lymphocyte Immunoglobulin for Prevention of Graft versus Host Disease in Patients Receiving Unrelated Donor Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:DKMS Group gGmbH

Obesity

Not recruiting

Study Comparing Retatrutide and Tirzepatide for Weight Loss in Adults with Obesity

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Prostate cancer

Not recruiting

Study of Apalutamide for Patients with High-Risk Prostate Cancer After Prostate Removal

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Universitaet Muenster

Non-Hodgkin's lymphoma+2

Not recruiting

Study on the Safety and Effectiveness of Brexucabtagene Autoleucel for Children and Teens with Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Brexucabtagene Autoleucel
  • Sponsor:Kite Pharma Inc.

Study on the Effectiveness and Safety of Osimertinib for Patients with Early-Stage Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Breast cancer

Not recruiting

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Rectal cancer

Not recruiting

Study Comparing Short Course Radiotherapy and Chemoradiotherapy with Fluorouracil, Calcium Folinate, and Capecitabine for Intermediate and High-Risk Rectal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Dermatitis atopic

Not recruiting

Long-Term Safety Study of Dupilumab for Children and Teens with Atopic Dermatitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer

Not recruiting

Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ahrensburg

What the registry says about research in the country

01 Respiratory Diseases

Innovative research focusing on asthma management and treatment, particularly examining new therapeutic approaches for patients with uncontrolled conditions. Studies are evaluating novel compounds to reduce exacerbation risks and improve symptom control.

  • Uncontrolled Asthma Studies
  • Gene Expression Analysis
  • Treatment Safety Evaluation

Multiple trials investigating both established and experimental treatments to enhance respiratory function and quality of life.

02 Pulmonary Conditions

Comprehensive studies addressing COPD and bronchiectasis, investigating new treatment modalities and their effects on exercise parameters and pulmonary function. Research includes assessment of dynamic hyperinflation and inflammatory responses.

  • Bronchiectasis Management
  • COPD Treatment Innovation
  • Exercise Performance Studies

Focus on developing targeted therapies for chronic respiratory conditions.

03 Specialized Respiratory Care

Advanced research into pulmonary fibrosis and allergic conditions, including long-term treatment evaluations and immunotherapy approaches. Studies examine safety profiles and efficacy of new therapeutic agents.

  • Pulmonary Fibrosis Treatments
  • Allergic Rhinitis Studies
  • Immunotherapy Research

Investigating innovative solutions for complex respiratory conditions requiring specialized care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.